RxDoctor Payments Data

Sean Rogers

Neurology · Alexandria, VANPI 1740504992

Payments from drug & device makers

$72,671in general payments, 2019–2025

Across 710 payments — averaging $102.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16K
  • MDD US Operations, LLC$15K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
  • Abbott$9K
  • Acorda Therapeutics, Inc$4K
  • AbbVie$2K
  • plus $12K from 43 others

What the payments were for

  • Consulting fees$11,78643%
  • Speaking & faculty fees$1,9647%
  • Travel & lodging$8573%
  • Food & beverage$13,03147%
  • Education$790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,671 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$167,908
Medicare patients
589
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa285$348,740
NuplazidPimavanserin Tartrate59$333,524
NeuproRotigotine76$133,136
GocovriAmantadine Hcl20$43,757
Rasagiline Mesylate204$35,329
Pramipexole ErPramipexole Di-Hcl88$33,350
NourianzIstradefylline11$25,211
Carbidopa-LevodopaCarbidopa/Levodopa577$13,827
CrexontCarbidopa/Levodopa13$12,145
Rivastigmine36$11,761
Donepezil Hcl681$8,397
Ropinirole ErRopinirole Hcl36$7,545
Memantine Hcl ErMemantine Hcl59$5,380
RivastigmineRivastigmine Tartrate47$4,744
Memantine Hcl186$4,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Crexont$339$360,885298 claims
Acadia Pharmaceuticals IncNuplazid$488$333,52459 claims
UCB, Inc.Neupro$543$133,13676 claims
MDD US Operations, LLCGocovri$14,640$43,75720 claims
Kyowa Kirin, Inc.Nourianz$670$25,21111 claims
Lilly USA, LLCTrulicity$341$3,05212 claims
Upsher-smith Laboratories LLCTopiramate$43$47076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.

Other neurology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →